This week in therapeutics




Licensing status

Publication and contact information



Survivin (BIRC5)

In vitro and mouse studies suggest inhibiting a BIRC5 splicing isoform could help treat cancer. In multiple primary tumor types, expression of the BIRC5 splicing isoform survivin-3B was greater than that in matched normal tissues. In multiple human cancer cell lines, small interfering RNA knockdown of the isoform increased sensitivity to chemotherapy compared with no knockdown. In a mouse xenograft model of human breast cancer, intratumoral injection of the isoform-targeted siRNA decreased tumor growth compared with injection of control siRNA. In this model, the isoform-targeted siRNA and chemotherapy had an additive effect on decreasing tumor growth compared with either agent alone. Next steps could include optimizing the BIRC5 splicing isoform-targeted siRNA for the treatment of solid tumors.

SciBX 6(32); doi:10.1038/scibx.2013.857
Published online Aug. 22, 2013

Unpatented; available for partnering

Végran, F. et al. Cancer Res.; published online July 15, 2013;
Contact: Romain Boidot, Center Georges François Leclerc, Dijon, France